Teva Pharmaceutical Industries (TEVA) reported a robust first quarter, achieving revenues of approximately $3.891 billion, slightly below the consensus expectation of $3.99 billion. The company has experienced growth for the ninth consecutive quarter, demonstrating a 5% increase in revenue in local currency terms compared to the previous year’s first quarter.
The firm's innovation-driven products continue to display strong momentum, collectively generating $589 million in revenue, marking a year-over-year growth of over 25%. Additionally, Teva reported robust performance in its generics segment across all regions, with biosimilars enhancing their portfolio offerings.
